- ABBV +1.85%
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
Yahoo Finance · 1 day ago
Search results
- 163.79Add to watchlist+2.98 (+1.85%)At close: Fri. May 3, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open161.16High164.25Low160.74
- Mkt Cap290.01BP/E (TTM)48.75Div & Yield6.20 & 3.79%
- Prev. Close160.8152 Wk. Low130.9652 Wk. High182.89
What analysts are sayingTop storiesRelated stocks
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
employees turning possibilities into reality for people and patients. Our products are approved in individual countries for specific uses and the information provided is governed by local regulations. Product availability, name and indicated use may vary by country. Please contact your local AbbVie office to learn more about products available ...
Oct 28, 2021 · 200,000+. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work.
Nov 30, 2023 · NORTH CHICAGO, Ill., and WALTHAM, Mass., Nov. 30, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved ...
Oct 11, 2023 · NORTH CHICAGO, Ill., Oct. 11, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses versu...
Dec 6, 2023 · NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across seve...
Feb 2, 2024 · February 02, 2024. AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results. Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense.
